Pharmaceuticals

Polaryx Therapeutics

Polaryx Therapeutics released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0538 (forecast USD -0.02)

Polaryx Therapeutics Receives FDA Fast Track Designation and Plans to Initiate Phase II Clinical Trials

Polaryx Therapeutics released FY2025 earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1978 (forecast USD -0.19)

Polaryx Therapeutics released FY2024 Q4 earnings on March 24 (EST), actual revenue USD 0, actual EPS USD -0.0184

Polaryx Therapeutics released FY2025 Q4 earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.034 (forecast USD -0.02)

Polaryx Therapeutics' PLX-200 Receives FDA Fast Track Designation

Polaryx Therapeutics released FY2024 9 Months Earnings on November 21, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.1827

Polaryx Therapeutics released FY2024 Q3 earnings on November 21 (EST), actual revenue USD 0, actual EPS USD -0.0202

Polaryx Therapeutics released FY2025 9 Months Earnings on November 21, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1677

Polaryx Therapeutics released FY2025 Q3 earnings on November 21 (EST), actual revenue USD 0, actual EPS USD -0.0312

Polaryx Therapeutics released FY2025 Q2 earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.0225

Polaryx Therapeutics released FY2025 semi-annual earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.1361

Polaryx Therapeutics released FY2024 Semi-Annual Earnings on September 19 (EST), with actual revenue of USD 0 and EPS of USD -0.9711

Polaryx Therapeutics released FY2024 Q2 earnings on September 19 (EST), actual revenue USD 0, actual EPS USD -0.0358

Polaryx Therapeutics released FY2024 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.8875

Polaryx Therapeutics released FY2023 annual earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.3535

Polaryx Therapeutics released FY2024 Q1 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.1266

Polaryx Therapeutics released FY2025 Q1 earnings on August 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1139

NewGenIvf

Agape ATP

Liminatus Pharma

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Infleqtion

Sunshine Biopharma

Wheeler Real Estate

Defiance 2X Daily Long Pure Quantum ETF

PLYX

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

StockTitan

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

XAIR

KALV

Short sellers have increased their positions in small-cap healthcare stocks, particularly those under $2 billion market cap, leading to heightened bearish sentiment. Sensei Biotherapeutics tops the list with a short interest of 63.85%, followed by KalVista Pharmaceuticals at 38.35%. Conversely, Beyond Air and Polaryx Therapeutics have minimal short interest at 0.50%. The healthcare sector has underperformed, with the Health Care Select Sector SPDR® Fund declining 6.23% year-to-date, despite the S&P 500's 5.62% rally.

businessinsider

Beyond Air

KalVista Pharma

Most and least shorted healthcare stocks with up to $2B market cap in May

Earnings Watch

Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0

Polaryx Therapeutics, Inc. (PLYX) received a Buy rating from Maxim Group, as reported by analyst Jason McCarthy. The company's shares closed at USD 5.27, with an analyst consensus of Moderate Buy and a price target of $10.00. McCarthy, who covers the Healthcare sector, has an average return of -14.2% and a 32.73% success rate on his stock recommendations.

Tip Ranks

Aprea Therapeutics

Moleculin Biotech

Plus Therapeutics

Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group

Polaryx Therapeutics, Inc. (PLYX) shares rose 10% after the FDA granted Fast Track Designation for all four indications in its SOTERIA Phase 2 trial. This includes PLX-200 for rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The trial aims to evaluate safety and efficacy, starting in late 2026. PLYX's stock closed at $5.70, down 6.86%, but pre-market trading saw it rise to $6.25.

nasdaq

Nasdaq

Polaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics (NASDAQ:PLYX) shares rose 4.9% to $6.47, despite a significant drop in trading volume. Maxim Group initiated coverage with a "buy" rating and a target price of $10.00. Currently, the stock holds an average "buy" rating among analysts, with a target price of $10.00. The company focuses on developing therapies for rare pediatric lysosomal storage disorders.

Market Beat

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher   - Time to Buy?

Polaryx Therapeutics(PLYX.US)

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards | PLYX Stock News

Most and least shorted healthcare stocks with up to $2B market cap in May

Polaryx Therapeutics | 10-K: FY2025 Revenue: USD 0

Polaryx Therapeutics, Inc. (PLYX) Receives a Buy from Maxim Group

Polaryx Shares Rise As FDA Grants Fast-track Status Across All SOTERIA Trial Indications

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | PLYX Stock News

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?